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Cutaneous Manifestations of Hyper
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ABSTRACT
Hyper-IgE syndrome (HIES) is a primary immunodeficiency disorder characterized by atopic manifestations
and susceptibility to infections with extracellular bacteria and fungi. Atopic manifestations include atopic
dermatitis-like skin lesion and extremely high serum IgE levels. Most of the extracellular bacterial infections are
caused by Staphylococcus aureus, which is associated with milder inflammation compared to normal. Recent
studies have revealed that the most cases of the HIES are caused by dominant negative mutations in STAT3
gene. Cutaneous manifestations of HIES includes newborn rash, eczematoid dermatitis, cold abscesses, mu-
cocutaneous candidiasis, and coarse texture of the facial skin. Impaired Th17 cell development due to the de-
fective IL-6 signaling in T cells and impaired induced regulatory T (iTreg) cell generation due to defective IL-10
signaling in dendritic cells may, at least in part, account for the cutaneous pathology of HIES.
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INTRODUCTION
Hyper IgE syndrome (also called Job’s syndrome;
#147060 and #243700 in OMIM) is a complex primary
immunodeficiency, characterized by atopic derma-
titis-like skin lesion associated with extremely high
serum IgE levels and susceptibility to infections with
extracellular bacteria and fungi.1,2 Non-immu-
nological abnormalities, including a distinctive facial
appearance, fracture with minor trauma, scoliosis,
hyper-extensive joints, and the retention of primary
teeth are also observed in most of the patients. The
original description of this syndrome was made in
1966, in which the two patients had recurrent staphy-
lococcal skin infections that lacked the typical fea-
tures of inflammation including warmness, redness,
and tenderness, therefore Davis and Wedgwood
coined the name “cold abscesses” for the unusual
skin manifestations.3 The syndrome was further in-
vestigated by Buckley and her colleagues, who identi-
fied that the recurrent staphylococcal skin infections
and cold-abscess formation in HIES were associated
with severe dermatitis and highly elevated serum IgE
levels.4 Later study established the multisystem na-
ture of HIES, in which the clinical manifestations are
not restricted to the immune system, but extend to
skeletal and connective tissue abnormalities.5 In
2006, we identified that a variant form of HIES,
autosomal-recessive HIES, is caused by the homozy-
gous null mutation in tyrosine kinase 2 (TYK2)
gene.6,7 Based on this finding, we identified that the
most of the patients of HIES have dominant negative
mutations in STAT3, responsible for the clinical mani-
festations of HIES.8-10 We now know HIES is caused
by “loss-of-function” mutations in STAT3, but we have
very limited knowledge of the molecular pathogene-
sis of HIES. In this article we will focus on the HIES
due to the dominant negative mutations in STAT3.
CLINICAL FEATURES OF HIES
The patients with HIES present extremely high se-
rum IgE levels, atopic dermatitis-like skin lesion, and
recurrent bacterial and fungal infections.11,12 The lev-
els of IgE in the serum are very high, which are often
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more than one hundred times higher than normal in-
dividuals. The atopic dermatitis-like skin lesion usu-
ally starts in the neonatal period as a newborn rash
and extracellular bacterial infections generally com-
mence in infancy or early childhood.13 The most com-
mon bacteria involved are Staphylococcus aureus, but
Streptococcus pneumoniae, Haemophilus influenza and
enteric gram-negative bacteria are also isolated in in-
fectious episodes of this syndrome.
In our series, most cases of HIES are sporadic, but
some familial cases of HIES have been reported,
either with autosomal dominant (AD)5 or autosomal
recessive (AR)14 mode of inheritance. Skeletal and
dental abnormalities, such as characteristic facial ap-
pearance, hyper-extensibility of joints, scoliosis, frac-
ture with minor trauma, and retained primary teeth,
are observed in sporadic and AD form, but not in the
AR form. Usually by the age of 16 years, almost all of
the patients show distinctive facial appearance;
coarse texture of facial skin, asymmetric facial ap-
pearance, prominent forehead, deep-set eyes, broad
nasal bridge, and bulky nasal tip. In this type of HIES,
pneumonia is frequently followed by the formation of
pneumatoceles, most likely due to the impaired re-
modeling capability of lung tissue. The AR form is
characterized by severe recurrent viral infections, ex-
treme eosinophilia, and neurological complications.14
HIES patients with AR-inheritance suffered from se-
vere viral infections such as chronic refractory mol-
luscum contagiosum and herpes simplex virus infec-
tions, which were not observed in AD form. A recent
study identified that HIES patients have decreased
number of central memory CD4+ and CD8+ T cells
and impaired ability to control varicella zoster virus
and Epstein-Barr virus latency compared to healthy
individuals.15 Interestingly, no pneumatoceles were
found in this form of HIES unlike in the AD type
HIES patients, even though the incidence of pneumo-
nia was equivalent in both types.
Clinical diagnosis of HIES is based on the criteria
established by Grimbacher et al., which scores clini-
cal findings such as the number of skin abscesses
(more than 4 times in a lifetime is 8 points) and pneu-
monia (more than 3 episodes in a lifetime is 8 points),
parenchymal lung abnormalities (pneumatocele is 8
points), characteristic facial appearance (if typical, 5
points), newborn rash (if present, 4 points), hyper-
extensibility (if present, 4 points) as well as labora-
tory findings such as high serum IgE concentrations
(>2000 IUml; 10 points) and eosinophilia (>800
mm3; 6 points).16 We clinically diagnose HIES if the
score of the patient is above 40 points, which is con-
firmed by molecular analysis.
CUTANEOUS MANIFESTATIONS
NEWBORN RASH
Most of HIES patients had a history of a newborn
rash,13 which usually begins in the first month of life.
Many of the patients were first diagnosed as neonatal
acne. The papules and pustules often began on the
face and scalp, then unlike neonatal acne, progressed
to entire upper body. In many cases, the rash had a
protracted course that developed into eczema, while
in some there was improvement or resolution follow-
ing treatment with oral antibiotics or topical corti-
costeroid. The histologic evaluation shows an eosino-
philic spongiotic dermatitis, eosinophilic folliculitis,
and superficial and deep perivascular dermatitis with
abundant eosinophils.17
The differential diagnosis of the newborn rash in-
cludes eosinophilic pustular folliculitis, erythema
toxicum neonatorum, and neonatal cephalic pustulo-
sis. The distribution, appearance, and histologic char-
acteristics of the newborn rash in HIES are similar to
those of eosinophilic pustular folliculitis. The age of
onset is usually older in eosinophilic pustular folliculi-
tis, with most cases occurring between ages 5 and 10
months rather than in the first month.18 Further-
more, eosinophilic pustular folliculitis of infancy does
not improve with antibiotic treatment but does im-
prove with topical steroid treatment.19 In contrast,
newborn rash of HIES frequently responds to antibi-
otic treatment. Erythema toxicum neonatorum can be
similar to newborn rash of HIES in appearance, age
of onset, distribution, and histologic characteristics. It
usually presents on the first or second day of life and
resolves within 5 days. Milder recurrences may occur
within 5 to 10 days after the original eruption.20 Simi-
lar to newborn rash of HIES, erythema toxicum neo-
natorum can been seen at birth. However, the new-
born rash of HIES is more severe and prolonged.
Neonatal cephaplic pustulosis is synonymous with
neonatal acne.21
ATOPIC DERMATITIS-LIKE SKIN LESION
Atopic dermatitis affects approximately 15% of chil-
dren in Westernized countries including Japan, which
is characterized by eczematoid skin lesions, dry skin,
and pruritus.22,23 Atopic dermatitis is a multifactorial
and heterogeneous disorder caused by the interac-
tion of environmental and genetic components. Entire
molecular pathogenesis of atopic dermatitis remains
unknown, but recent studies indicate that a defective
skin barrier function is one of the mechanisms of this
disorder. A loss-of-function mutation in the gene en-
coding filaggrin is identified as an important risk fac-
tormolecular cause for atopic dermatitis.24,25 Filag-
grin protein is located in the granular layers of the
epidermis. In the differentiation of keratinocytes, the
protein is dephosphorylated and cleaved into 10 to 12
almost identical 27 kDa filaggrin molecules, which
aggregate in the keratin cytoskeleton to form a dense
protein-lipid matrix. This structure prevents epider-
mal water loss and blocks the entry of innoxious aller-
gens and infectious microorganisms.
There are some different descriptions of skin mani-
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festations of HIES. Davis et al. referred as “infected
eczematoid skin lesions.”3 Buckley et al. mentioned
as “a generalized dermatitis that was similar to, but
atypical for atopic dermatitis.”4 Erlewyn-Lajeunesse
also noted that the distribution of the rash in HIES
was atypical for atopic dermatitis.26 Anyhow, all the
previous studies equivalently claim almost all the
HIES patients have eczematoid, i.e. atopic dermatitis-
like skin manifestations.
Skin manifestations of HIES and atopic dermatitis
both are associated with eosinophilia and high serum
IgE levels. The rash in HIES is typically papular and
pruritic. Lichenification is frequently observed, in
which epidermis becomes hypertrophied resulting in
thickening of the skin and exaggeration of the skin
markings. The rash observed in HIES is very similar
to atopic dermatitis clinically and histopathologically,
but the distribution of the rash is reportedly slightly
different. The atopic dermatitis typically involves the
flexural surfaces of the body. The skin involvement in
HIES is located in their face and extensor surfaces.
However, the location of atopic dermatitis changes
with age, thus it is not clear the previously reported
difference is associated with an essential difference
between the two. Atopic dermatitis is also often asso-
ciated with a history of other allergic disorders such
as food allergy, asthma, and allergic rhinitis, which is
lacking in HIES. Staphylococcal infections in atopic
dermatitis is usually superficial whereas HIES pa-
tients develop deep-seated abscesses. Mucocutane-
ous candidiasis is also a frequent complications of
HIES, but not in atopic dermatitis. Skin lesions of
atopic dermatitis usually has its onset after two to
four months of age, whereas HIES have symptoms
before one month of age.27
Skin abnormalities in HIES are not confined to
atopic dermatitis-like skin lesion, but the dermatitis is
invariably colonized with Staphylococcus aureus and
becomes infected, thus leading to the condition for
more severe dermatitis. These acute episodes can be
cured, but recurrences are not rare if patients fail to
take prophylactic antibiotics such as trimethoprim-
sulfamethoxazole. Coarse texture of the facial skin in
HIES patients is frequently observed. Older subjects
with HIES, despite having no history of severe acne,
show distinctive thick and doughy texture of the fa-
cial skin. This might be related to the impaired re-
modeling in facial skin, but exact nature of this cuta-
neous manifestation remains to be elucidated.
COLD ABSCESSES
Cold abscesses are a part of the original clinical de-
scription defining triad of HIES. An originally-
reported patient had 6 cm × 10 cm mass in the ante-
rior neck, but was afebrile. The mass was only
slightly tender but not warm. A surgeon thought that
it was an enlarged but not infected thyroglossal duct
cyst, but it turned out to contain 200 ml of pus. Cold
abscess is defined as an abscess with little or no evi-
dence of inflammatory response, which can present
in any part of the body, fluctuant, non-tender, and
non-erythematous masses that may be mistaken for
cysts or benign tumors. The abscess may be large
and the infectious agent is almost always Staphylococ-
cus aureus. Recently, the incidence of cold abscesses
was significantly decreased probably due to early ad-
ministration of antibiotics against any signs of infec-
tions and prophylactic anti-staphylococcal antibiotics
to the HIES patients.
Acute-phase responses, such as increased serum
C-reactive protein levels during infections, were di-
minished in the HIES patients. STAT3 was originally
identified as a protein binding to the IL-6 responsive
element in the genes encoding hepatic acute phase
proteins.28 Thus, the apparent lack of classical inflam-
matory responses in HIES patients could be attrib-
uted to defective signaling of IL-6, but exact molecu-
lar mechanism remains unknown.
MUCOCUTANEOUS CANDIDIASIS
Approximate 60% of the HIES patients present with
chronic mucocutaneous candidiasis.29 Oral candidia-
sis starts very early in life and chronic paronychia of
several fingers was found in about half of the patients.
This symptom is effectively managed with a combina-
tion of oral and topical anti-fungal agents.
Recent studies have demonstrated that Th17 cell
development and function is impaired in HIES.10,30-33
Th17 cytokines play a crucial role in protecting
against mucocutaneous candidiasis.34,35 Furthermore
autosomal recessive IL-17RA deficiency and autoso-
mal dominant IL-17F deficiency result in chronic mu-
cocutaneous candidiasis. These results indicate that
IL-17A and IL-17F are essential for mucocutaneous
immunity against Candida albicans in humans. Re-
cent studies also demonstrated that most of the pa-
tients with chronic mucocutaneous candidiasis have
constitutive activating mutations in STAT1 gene,36,37
leading to defective Th17 cell responses. These find-
ings strongly indicate that mucocutaneous candidia-
sis in HIES is resulted from defective Th17 cell devel-
opment and function.
MOLECULAR MECHANISMS OF HIES
Th17 CELLS AND SKIN STAPHYLOCOCCAL
AND FUNGAL INFECTIONS
STAT3 plays a critical role in signal transduction for
many cytokines and growth factors, including those
of the γc family, the gp130 family, the IL-10 family,
and receptor-type tyrosine kinases. STAT3 also func-
tions as a transcription factor, binding to promoter re-
gions and initiating transcription of its target genes.
STAT3 is crucial for Th17 cell development in hu-
mans and mice.10,30-33 Th17 cells―a subset of helper
T cells producing cytokines including IL-17A, IL-17F
and IL-22―, have been extensively studied as an in-
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ducer of autoimmune disorders.38-42 Th17 cells also
play a key role in host defense against extracellular
bacteria and fungi.43,44 Most of the staphylococcal
and candida infections occurring in patients with
HIES are confined to the epithelium. Previous reports
indicated that the levels of production of Th17 cytoki-
nes including IL-17A, IL-17F, and IL-22 by activated T
cells from HIES patients are much lower than those
from control subjects, whereas the production of
other proinflammatory cytokines, including IFNγ, IL-
1β and TNFα is equivalent. Primary keratinocytes
and bronchial epithelial cells do not produce suffi-
cient amounts of neutrophil-recruiting chemokines
and β-defensins in response to the supernatants of ac-
tivated HIES T cells. The neutralization of Th17 cy-
tokines in the supernatants of activated control T
cells decreases the production of the chemokines and
defensins. By contrast, primary dermal fibroblasts
and endothelial cells respond equally well to the su-
pernatants from patients and controls. Furthermore,
primary keratinocytes and bronchial epithelial cells
do not produce sufficient amounts of neutrophil-
recruiting chemokines and β-defensins in response to
Th17 cytokines, but produce sufficient amounts of
neutrophil-recruiting chemokines and β-defensins in
response to Th17 cytokines and proinflammatory cy-
tokines. Collectively, these results indicate that
keratinocytes and bronchial epithelial cells respond
differently from other types of cells to Th17 cytoki-
nes, with Th17 cytokines playing a more important
role in the production of the chemokines and β-
defensins in epithelial cells. This observation sug-
gested that Th17 cytokines play a crucial role in hu-
man host defense against Staphylococcus aureus and
Candida albicans, particularly at the surface barriers
of the body. These findings underscore the physi-
ological role of Th17 cytokines in the protection
against extracellular pathogens in humans.
Topical application of Th17 cytokines or down-
stream products of Th17 cytokines might be benefi-
cial for the management of staphylococcal and can-
dida infections, if conventional therapy is not suffi-
cient to control this disorder.
INDUCED TREG (iTreg) CELLS AND ATOPIC
DERMATITIS
Effector Th2 cells are the major cell type responding
to allergens and produce Th2 cytokines including IL-
4, IL-5, IL-9 and IL-13. These Th2 cytokines induce
changes in blood vessels, upregulating adhesion
molecules and eosinophil recruiting chemokines.
Th2 cytokines also induce class switching to IgE.45
Recently identified cytokines including IL-25, IL-31,
and IL-33, also participate in Th2 cell-mediated aller-
gic diseases.46-48 Th1 cytokines also play a role in the
pathogenesis of atopic dermatitis contributing at a
later time-point in epithelial cells.49
The dendritic cells play a crucial role for induction
and suppression of immune responses. We found that
DCs of HIES patients display defective IL-10 signal-
ing, resulting in impairment of the suppression of cy-
tokine production and T cell proliferation.50 The gen-
eration of Foxp3+ iTreg cells educated by IL-10
treated dendritic cells was also impaired in HIES. IL-
10 upregulates the expression of PD-L1 and ILT-4 on
the surface of dendritic cells, and both of the mole-
cules play a critical role for the induction of Foxp3+
iTreg cells. IL-10 treated dendritic cells induce iTreg
cells as efficiently as TGF-β and the combination of
IL-10 treated dendritic cells and TGF-β synergistically
upregulates the induction of iTreg cells. These re-
sults suggest that IL-10 signaling in dendritic cells
may be crucial for the generation of iTreg cells in
vivo, to maintain an appropriate Th2-Treg cell bal-
ance. FOXP3+ Treg cells mediate peripheral toler-
ance and play a central role in determining several
immune diseases, including autoimmunity, chronic
infections, tumors, and allergies.51 FOXP3+ Treg cells
is involved in protecting humans against allergic dis-
eases, because patients with immunodeficiency, poly-
endocrinopathy, and enteropathy, X-linked (IPEX)
syndrome suffer from allergic symptoms. PBMCs
from atopic patients proliferate more extensively and
produce more Th2 cytokines in response to allergen
than do PBMCs from non-atopic healthy individu-
als.52
CONCLUSION AND PERSPECTIVE
The identification of a molecular cause of HIES leads
to the elucidation of the molecular mechanisms of cu-
taneous manifestations of HIES, which revealed the
critical function of STAT3 in the signal transduction
of multiple cytokines involved in the epithelial immu-
nity in humans. The investigation of dominant nega-
tive mutations in STAT3 resulting in atopic dermatitis
and the susceptibility to staphylococcal and candida
infections highlight the multiple and critical roles of
STAT3 for its effector and regulating functions in
vivo. Furthermore, the identification of molecular
mechanisms of cutaneous manifestations of HIES
may bring about an improvement in controlling
atopic dermatitis and staphylococcal and candida in-
fections for the future.
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